Health & Beauty

On April 9th, the 2023 China Pharmaceutical International Cooperation Conference and the 5th China Pharmaceutical Products Internationalization Forum were held in Shenzhen. The current conference, co hosted by the China Chamber of Commerce for Import and Export of Medical and Health Products, China Pharmaceutical Group Co., Ltd., Shenzhen Development and Reform Commission, and Shenzhen Pingshan District People's Government, focuses on the theme of "open cooperation, innovative development". Based on the current new situation and requirements of domestic and international development, it integrates resources from medical, research, government, enterprises, and investors to jointly build an industrial innovation ecosystem and seek high-quality development paths; By grafting domestic and foreign resources, actively seeking new ideas for the internationalization development of China's medical and health industry, and exploring new paths for pharmaceutical supervision and high-quality industrial development in the Greater Bay Area.

In recent years, China has continuously introduced a series of policy measures to deepen the reform of the medical and health system, providing institutional support for the high-quality development of the pharmaceutical and health industry, and also providing institutional guarantees for the industry to carry out comprehensive international trade cooperation. Meng Dongping, Secretary of the Party Committee of the Medical Insurance Chamber of Commerce, stated that the 20th National Congress of the Communist Party of China and this year's two sessions have pointed out the direction and goals for the development of China's pharmaceutical and health industry in the new era. The Chinese pharmaceutical industry and its international development have shown new characteristics. Institutional openness has created a favorable business environment for the pharmaceutical and health industry to "go global" and "bring in", greatly enhancing the driving force for advanced global medical forces to seek cooperation with China and achieve integrated development. The Chinese pharmaceutical and health industry, which is moving towards the center of the world stage, has burst into vitality and vitality in the process of reform, opening up, and innovative development. In the face of century long changes and current severe challenges, only openness can alleviate the difficulties of development, harness the power of cooperation and innovation, and seek the benefits of sharing. Meng Dongping also emphasized that Chinese pharmaceutical and health industry enterprises that are going international should have a clear understanding of their own shortcomings and weaknesses, and regard innovation and high-quality development as the foundation and development path.

To support the development of international trade in pharmaceuticals, the Ministry of Commerce has done a solid job in related work, introduced multiple rounds of stable foreign trade policies and measures, and helped foreign trade enterprises alleviate difficulties and difficulties; Accelerate the high-quality construction of 40 national foreign trade transformation and upgrading bases in the pharmaceutical industry; Fully leverage the role of platforms such as the Canton Fair to promote the import and export of pharmaceutical products. Li Shuo, Deputy Director of the Foreign Trade Department of the Ministry of Commerce, stated that in the future, the Ministry of Commerce will continue to support the high-quality development of pharmaceutical product trade, and hopes that enterprises can seize opportunities and seize the opportunity to jointly promote international trade cooperation in the pharmaceutical industry to a new level.

In order to assist biopharmaceutical enterprises in "going global", Liu Yaqin, Director of the Drug Price Monitoring Department of the Price Cost Investigation Center of the National Development and Reform Commission, suggested strengthening top-level design and policy coordination, setting innovative drug prices in China from the perspective of "selling globally", vigorously developing supporting service industries, fully leveraging the role of international organizations and trade cooperation and exchange platforms, increasing financial support for finance, taxation, and international talent introduction and training, Further enhance the level of trade and investment liberalization and facilitation.

Enterprises are also actively taking action. During the 14th Five Year Plan period, China National Pharmaceutical Group will vigorously implement the "Four Beams and Eight Pillars, Top 100 Billions" innovation driven overall development strategy plan for the entire lifecycle, entire industry chain, and entire ecosystem, and accelerate the construction of a world-class comprehensive pharmaceutical and health industry group with global competitiveness. Jin Bin, deputy general manager and press spokesman of Sinopharm Group, said that Sinopharm Group will continue to play the leading role in China's pharmaceutical industry, help build a new development pattern of domestic and international double circulation, continue to do a good job in the global layout of medicine internationalization, focus on deepening the cooperation in public health projects of the "the Belt and Road", and actively help promote the construction of a community of human health.

At the meeting, the Medical Insurance Chamber of Commerce signed a strategic cooperation agreement with the Pingshan District Government of Shenzhen. In the future, both parties will leverage their respective functional advantages to help enterprises explore the international trade market and accelerate the development of the biopharmaceutical and big health industries. Pingshan is a gathering area for Shenzhen's advanced manufacturing industry and a pilot area for future industries. As one of the three leading industries in Pingshan, the biopharmaceutical industry is an important engine and future growth pole for the development of the biopharmaceutical industry in Shenzhen, gathering over a thousand enterprises such as Sanofi Pasteur and New Industry Biology.

On the eve of the opening of the Pharmaceutical International Cooperation Conference, the Guangdong Hong Kong Macao Greater Bay Area Medical System Cooperation and Payment Reform Innovation Conference was held in Shenzhen on April 8th. The Guangdong Hong Kong Macao Greater Bay Area is an important area for the gathering of China's biopharmaceutical industry, with the advantages of a pioneering reform and opening up window and an international location that radiates globally. With the assistance of various policies, a healthy bay area with innovative vitality is gradually emerging.

Macao has a wide variety of imported drugs and medical devices, with relatively abundant medical resources. According to Li Shien, Deputy Director of the Macau Drug Administration, the agency continues to simplify the approval process to ensure the availability of innovative drugs in Macau. Through the policy of "Hong Kong Macao Pharmaceutical Equipment Connect", new drugs that are urgently needed in clinical practice and have been listed in Macau can also be used in designated medical institutions in the Greater Bay Area to meet the medical needs of the Greater Bay Area and promote innovation and integrated development of the medical system in the Greater Bay Area.

In recent years, new progress has been made in health cooperation between Guangdong, Hong Kong, and Macao, opening a new chapter in the integrated development of healthcare in the Bay Area. According to reports, as of March 19th, since the implementation of the "Hong Kong Macao Medical Device Connect" policy, a total of 23 imported drugs (54 batches in total) and 13 imported medical devices (15 batches in total) have been approved, benefiting 2052 people. Xu Qingfeng, a member of the Party Group and Deputy Director of the Guangdong Provincial Health Commission, stated that the Guangdong Provincial Health System will promote the release of the "multiplier effect" and "chemical reaction" of the advantages of Guangdong Hong Kong Macao's pharmaceutical development, creating a new situation for Guangdong Hong Kong Macao's health cooperation and development.